Global Human Embryonic Stem Cell Laws and Policies and Their Influence on Stem Cell Tourism
By Nishakanthi Gopalan et al.,
Biotechnology Law Report
| 10. 09. 2018
Abstract
Stem cell (SC) technology has spurred many debates among experts which highlight both the deficiency of current regulation and the growing need for better oversight. The benefit of better regulating SC technology is easily understood by studying the variety of laws and policies available. Previous compilations, last published in 2009, are outdated, calling for an update. Therefore, this study aims to bring up to date the laws and policies relating to human embryonic stem cells (HESC) and to identify emerging trends in regulation. The review of numerous legal documents, including bills and legislation, accessed through official government portals, found that all developed countries have sound legislation promoting research. While some developed nations have gaps within their otherwise-sound regulation, a more pressing issue is growing travel for treatment (“SC tourism”) to developing and under-developed countries where SC technology is under- or unregulated. Therefore, SC tourism is no longer a country issue; rather, it is a universal dilemma requiring international effort for a resolution.
Related Articles
By Katie Hunt, CNN | 07.30.2025
Scientists are exploring ways to mimic the origins of human life without two fundamental components: sperm and egg.
They are coaxing clusters of stem cells – programmable cells that can transform into many different specialized cell types – to form...
By Ewen Callaway, Nature | 08.04.2025
For months, researchers in a laboratory in Dallas, Texas, worked in secrecy, culturing grey-wolf blood cells and altering the DNA within. The scientists then plucked nuclei from these gene-edited cells and injected them into egg cells from a domestic dog ...
By Kristel Tjandra, Genetic Engineering & Biotechnology News | 07.30.2025
CRISPR has taken the bioengineering world by storm since its first introduction. From treating sickle cell diseases to creating disease-resistant crops, the technology continues to boast success on various fronts. But getting CRISPR experiments right in the lab isn’t simple...
By Arthur Caplan and James Tabery, Scientific American | 07.28.2025
An understandable ethics outcry greeted the June announcement of a software platform that offers aspiring parents “genetic optimization” of their embryos. Touted by Nucleus Genomics’ CEO Kian Sadeghi, the $5,999 service, dubbed “Nucleus Embryo,” promised optimization of...